Page 1573 - Williams Hematology ( PDFDrive )

1548 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1549

254. Byrd JC, Rai K, Peterson BL, et al: Addition of rituximab to fludarabine may prolong 278. Byrd JC, Brown JR, O’Brien S, et al: Ibrutinib versus ofatumumab in previously treated
progression-free survival and overall survival in patients with previously untreated chronic lymphoid leukemia. N Engl J Med 371:213–223, 2014.
chronic lymphocytic leukemia: An updated retrospective comparative analysis of 279. Kamel S, Horton L, Ysebaert L, et al: Ibrutinib inhibits collagen-mediated but not ADP-
CALGB 9712 and CALGB 9011. Blood 105:49–53, 2005. mediated platelet aggregation. Leukemia 29:783–787, 2015.
255. Woyach JA, Ruppert AS, Heerema NA, et al: Chemoimmunotherapy with fludara- 280. Godiwala N, Maddocks K, Westbrook T, et al: Covariation of psychological and inflam-
bine and rituximab produces extended overall survival and progression-free survival matory variables in patients with chronic lymphocytic leukemia receiving ibrutinib.
in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712. J Clin J Clin Oncol 32:5s, (suppl; abstr 7057), 2014.
Oncol 29:1349–1355, 2011. 281. Woyach JA, Furman RR, Liu TM, et al: Resistance mechanisms for the Bruton’s tyrosine
256. Robak T, Dmoszynska A, Solal-Celigny P, et al: Rituximab plus fludarabine and cyclo- kinase inhibitor ibrutinib. N Engl J Med 370:2286–2294, 2014.
phosphamide prolongs progression-free survival compared with fludarabine and cyclo- 282. Burger JA, Keating MJ, Wierda WG, et al: Safety and activity of ibrutinib plus rituximab
phosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study.
28:1756–1765, 2010. Lancet Oncol 15:1090–1099, 2014.
257. Wierda W, O’Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophos- 283. Herman SE, Gordon AL, Wagner AJ, et al: Phosphatidylinositol 3-kinase-delta inhib-
phamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J itor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia
Clin Oncol 23:4070–4078, 2005. by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116:2078–2088,
258. Keating MJ, O’Brien S, Albitar M, et al: Early results of a chemoimmunotherapy reg- 2010.
imen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic 284. So L, Fruman DA: PI3K signalling in B- and T-lymphocytes: New developments and
lymphocytic leukemia. J Clin Oncol 23:4079–4088, 2005. therapeutic advances. Biochem J 442:465–481, 2012.
259. Tam CS, O’Brien S, Wierda W, et al: Long-term results of the fludarabine, cyclophos- 285. Bunney TD, Katan M: Phosphoinositide signalling in cancer: Beyond PI3K and PTEN.
phamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Nat Rev Cancer 10:342–352, 2010.
Blood 112:975–980, 2008. 286. Chantry D, Vojtek A, Kashishian A, et al: P110delta, a novel phosphatidylinositol
260. Strati P, Wierda W, Burger J, et al: Myelosuppression after frontline fludarabine, cyclo- 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in
phosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis leukocytes. J Biol Chem 272:19236–19241, 1997.
of persistent and new-onset cytopenia. Cancer 119:3805–3811, 2013. 287. Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic
261. Benjamini O, Jain P, Trinh L, et al: Second cancers in patients with chronic lymphocytic lymphocytic leukemia. N Engl J Med 370:997–1007, 2014.
leukemia who received frontline fludarabine, cyclophosphamide and rituximab ther- 288. Kharfan-Dabaja MA, Wierda WG, Cooper LJ: Immunotherapy for chronic lympho-
apy: Distribution and clinical outcomes. Leuk Lymphoma 1–8, 2014. cytic leukemia in the era of BTK inhibitors. Leukemia 28:507–517, 2014.
262. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine 289. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients
and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study.
open-label, phase 3 trial. Lancet 376:1164–1174, 2010. J Clin Oncol 24:5343–5349, 2006.
263. Stilgenbauer S, Schnaiter A, Paschka P, et al: Gene mutations and treatment outcome in 290. Maddocks K, Ruppert AS, Browning R, et al: A dose escalation feasibility study of
chronic lymphocytic leukemia: Results from the CLL8 trial. Blood 123:3247–3254, 2014. lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
264. Tam CS, O’Brien S, Plunkett W, et al: Long-term results of first salvage treatment in CLL Leuk Res 38:1025–1029, 2014.
patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 291. Wendtner CM, Hillmen P, Mahadevan D, et al: Final results of a multicenter phase
124:3059–3064, 2014. 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic
265. Foon KA, Boyiadzis M, Land SR, et al: Chemoimmunotherapy with low-dose fludara- leukemia. Leuk Lymphoma 53:417–423, 2012.
bine and cyclophosphamide and high dose rituximab in previously untreated patients 292. Badoux XC, Keating MJ, Wen S, et al: Lenalidomide as initial therapy of elderly patients
with chronic lymphocytic leukemia. J Clin Oncol 27:498–503, 2009. with chronic lymphocytic leukemia. Blood 118:3489–3498, 2011.
266. Lamanna N, Jurcic JG, Noy A, et al: Sequential therapy with fludarabine, high-dose 293. Chen CI, Bergsagel PL, Paul H, et al: Single-agent lenalidomide in the treatment of
cyclophosphamide, and rituximab in previously untreated patients with chronic lym- previously untreated chronic lymphocytic leukemia. J Clin Oncol 29:1175–1181, 2011.
phocytic leukemia produces high-quality responses: Molecular remissions predict for 294. Awan FT, Johnson AJ, Lapalombella R, et al: Thalidomide and lenalidomide as new
durable complete responses. J Clin Oncol 27:491–497, 2009. therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 51:
267. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients 27–38, 2010.
with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase 295. James DF, Werner L, Brown JR, et al: Lenalidomide and rituximab for the initial treatment of
II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29: patients with chronic lymphocytic leukemia: A multicenter clinical-translational study
3559–3566, 2011. from the chronic lymphocytic leukemia research consortium. J Clin Oncol 32:2067–
268. Fischer K, Cramer P, Busch R, et al: Bendamustine in combination with rituximab 2073, 2014.
for previously untreated patients with chronic lymphocytic leukemia: A multicenter 296. Badoux XC, Keating MJ, Wen S, et al: Phase II study of lenalidomide and rituximab as
phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
30:3209–3216, 2012. J Clin Oncol 31:584–591, 2013.
269. Eichhorst B, Fink A, Busch R, et al: Frontline chemoimmunotherapy with fludarabine 297. Costa LJ, Fanning SR, Stephenson J Jr., et al: Sequential ofatumumab and lenalidomide
(F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in com- for the treatment of relapsed and refractory chronic lymphocytic leukemia and small
parison to bendamustine (B) and rituximab (BR) in previously untreated and physically lymphocytic lymphoma. Leuk Lymphoma 1–15, 2014.
fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis 298. Shanafelt TD, Ramsay AG, Zent CS, et al: Long-term repair of T-cell synapse activity
of an international, randomized study of the German CLL Study Group (GCLLSG) in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in
(CLL10 Study). ASH Abstracts 2014 19, 2014. previously untreated chronic lymphocytic leukemia (CLL). Blood 121:4137–4141, 2013.
270. Kay NE, Wu W, Kabat B, et al: Pentostatin and rituximab therapy for previously 299. Lee BN, Gao H, Cohen EN, et al: Treatment with lenalidomide modulates T-cell immu-
untreated patients with B-cell chronic lymphocytic leukemia. Cancer 116:2180–2187, nophenotype and cytokine production in patients with chronic lymphocytic leukemia.
2010. Cancer 117:3999–4008, 2011.
271. Bertazzoni P, Rabascio C, Gigli F, et al: Rituximab and subcutaneous cladribine in 300. Arumainathan A, Kalakonda N, Pettitt AR: Lenalidomide can be highly effective in
chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome
Lymphoma 51:1485–1493, 2010. 17p. Eur J Haematol 87:372–375, 2011.
272. Robak T, Smolewski P, Cebula B, et al: Rituximab plus cladribine with or without cyclo- 301. Lapalombella R, Andritsos L, Liu Q, et al: Lenalidomide treatment promotes CD154
phosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. expression on CLL cells and enhances production of antibodies by normal B cells
Eur J Haematol 79:107–113, 2007. through a PI3-kinase-dependent pathway. Blood 115:2619–2629, 2010.
273. Robak T, Smolewski P, Cebula B, et al: Rituximab combined with cladribine or with 302. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in
cladribine and cyclophosphamide in heavily pretreated patients with indolent lymph- chronic lymphoid leukemia. N Engl J Med 365:725–733, 2011.
oproliferative disorders and mantle cell lymphoma. Cancer 107:1542–1550, 2006. 303. Gill S, June CH: Going viral: Chimeric antigen receptor T-cell therapy for hematologi-
274. Honigberg LA, Smith AM, Sirisawad M, et al: The Bruton tyrosine kinase inhibitor cal malignancies. Immunol Rev 263:68–89, 2015.
PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease 304. Kalos M, Levine BL, Porter DL, et al: T cells with chimeric antigen receptors have
and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075–13080, 2010. potent antitumor effects and can establish memory in patients with advanced leukemia.
275. Woyach JA, Smucker K, Smith LL, et al: Prolonged lymphocytosis during ibrutinib Sci Transl Med 3:95ra73, 2011.
therapy is associated with distinct molecular characteristics and does not indicate a 305. ABT-199 shows effectiveness in CLL. Cancer Discov 4:OF7, 2014.
suboptimal response to therapy. Blood 123:1810–1817, 2014. 306. Souers AJ, Leverson JD, Boghaert ER, et al: ABT-199, a potent and selective BCL-2
276. O’Brien S, Furman R, Coutre S, et al: Independent evaluation of ibrutinib efficacy inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202–208,
3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/ 2013.
small lymphocytic leukemia including deletion 17p disease. J Clin Oncol 32:5s, 2014. 307. Topp MS, Kufer P, Gokbuget N, et al: Targeted therapy with the T-cell-engaging anti-
277. O’Brien S, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for elderly patients body blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage
with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, acute lymphoblastic leukemia patients results in high response rate and prolonged leu-
multicentre, phase 1b/2 trial. Lancet Oncol 15:48–58, 2014. kemia-free survival. J Clin Oncol 29:2493–2498, 2011.

Kaushansky_chapter 92_p1527-1552.indd 1548 9/18/15 10:49 AM